Interview conducted by Didier Testot Founder of LA BOURSE ET LA VIE TV
Stanislas Veillet, CEO of Biophytis, reviews the first results of the SARA-INT Phase 2 clinical trial with Sarconeos (BIO101) in sarcopenia and looks forward to a Phase 3 development.